Targeted therapy for pediatric central nervous system tumors harboring mutagenic tropomyosin receptor kinases
The family of the neurotrophic tyrosine kinase receptor (NTRK) gene encodes for members of the tropomyosin receptor kinase (TRK) family. Rearrangements involving NTRK1/2/3 are rare oncogenic factors reported with variable frequencies in an extensive range of cancers in pediatrics and adult populatio...
Main Authors: | Selene Cipri, Francesco Fabozzi, Giada Del Baldo, Giuseppe Maria Milano, Luigi Boccuto, Andrea Carai, Angela Mastronuzzi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1235794/full |
Similar Items
-
Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy
by: Selene Cipri, et al.
Published: (2023-06-01) -
Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
by: Tingting Jiang, et al.
Published: (2021-02-01) -
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
by: Antoine Italiano, et al.
Published: (2020-11-01) -
Cerebrospinal Fluid Levels of AFP and hCG: Validation of the Analytical Method and Application in the Diagnosis of Central Nervous System Germ Cell Tumors
by: Annamaria D'Alessandro, et al.
Published: (2021-10-01) -
How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care
by: Selene Cipri, et al.
Published: (2022-10-01)